<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758248</url>
  </required_header>
  <id_info>
    <org_study_id>Gene Polymorphism</org_study_id>
    <nct_id>NCT03758248</nct_id>
  </id_info>
  <brief_title>The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI</brief_title>
  <official_title>The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual antiplatelet therapy with aspirin and thienopyridines is an essential treatment in&#xD;
      patients undergoing percutaneous coronary intervention (PCI). However, despite intensified&#xD;
      antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent&#xD;
      occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. Some&#xD;
      patients develop bleeding event because of the improper dosage and covariation. This&#xD;
      observational study is designed for clarifying the Influence of gene polymorphism on clinical&#xD;
      outcomes in patients undergoing PCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing PCI who received dual antiplatelet therapy with both aspirin (100mg) and&#xD;
      P2Y12 inhibitors in standard dosage were enrolled. Investigators examined plasma biomarkers&#xD;
      for platelet activation and DNA in those patients, and then analyzed the CYP2C19 genetic&#xD;
      polymorphism to examine the influence of this genetic variation on the several biomarkers for&#xD;
      platelet activation and bleeding event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Patients with treatment-related major bleeding event as assessed by the Bleeding Academic Research Consortium (BARC) bleeding criteria</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The major bleeding event was a composite endpoint of BARC bleeding type 3 and 5), defined according to the BARC bleeding criteria, which was used widely in this field. BARC bleeding was defined as follows: BARC type 1, any bleeding that is not actionable; type 2, any overt, actionable sign of bleeding; type 3a, overt bleeding with a haemoglobin drop of 3-5 g/dL or any transfusion; type 3b, overt bleeding with a haemoglobin drop &gt;5 g/dL, requiring vasopressors, surgical intervention, or due to cardiac tamponade; type 3c, any intracranial or intraocular bleeding; and finally type 5, any bleeding resulting in death (type 4 was coronary artery bypass graft-related bleeding, which was excluded). Investigator will get all the information through regular return visit and telephone follow-up after discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>A composite of death, myocardial infarction, stroke, stent thrombosis, and ischemia-driven revascularization</description>
  </secondary_outcome>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Antiplatelet Therapy</condition>
  <condition>CYP2C19 Polymorphism</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>CYP2C19</intervention_name>
    <description>The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19*17 carriers) or higher (CYP2C19*2 carriers) risk of major adverse cardiovascular events.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gene polymorphism is measured by using whole blood in patients undergoing PCI.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PCI patients in Beijing Anzhen Hospital from August 2018 to August 2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patients undergoing PCI&#xD;
&#xD;
          2. More than 18 years old&#xD;
&#xD;
          3. Treated with aspirin and P2Y12 inhibitors (clopidogrel or ticagrelor)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inability to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yujie Zhou, PhD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujie Zhou, PhD,MD</last_name>
    <phone>8613901330652</phone>
    <email>azzyj12@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhou, MD, PhD</last_name>
      <phone>8613901330652</phone>
      <email>azzyj12@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yujing Cheng, MD</last_name>
      <phone>8613426481193</phone>
      <email>13426481193@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yujie Zhou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yujie Zhou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Genotype-guided therapy</keyword>
  <keyword>CYP2C19 Polymorphism</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

